CXCL8 and rheumatoid arthritis: From a clinical perspective, our findings support the concept that interference with the production/activity of IL-8 and ACPAs may have benefits in inhibiting/preventing bone erosion, particularly in ACPA-positive RA patients and ACPA-positive individuals at risk of developing RA.